Intellia Therapeutics (NTLA) Non-cash Items (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Non-cash Items data on file, last reported at $4.1 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $4.1 million, down 8.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 8.07% YoY), and the FY2025 annual result was $4.1 million, down 3.63% from the prior year.
• Non-cash Items grew to $4.1 million in Q1 2026 per NTLA's latest filing, from $50000.0 in the prior quarter.
• Over five years, Non-cash Items peaked at $204.9 million in Q1 2022 and troughed at $50000.0 in Q4 2025.
• A 5-year average of $30.9 million and a median of $4.2 million in 2025 frame the typical range for Non-cash Items.
• On a YoY basis, Non-cash Items climbed as much as 5815.27% in 2022 and fell as far as 99.74% in 2022.
• A 5-year view of Non-cash Items shows it stood at $93.1 million in 2022, then plunged by 61.42% to $35.9 million in 2023, then sank by 99.03% to $350000.0 in 2024, then plunged by 85.71% to $50000.0 in 2025, then soared by 8181.92% to $4.1 million in 2026.
• Business Quant data shows NTLA's Non-cash Items at $4.1 million in Q1 2026, $50000.0 in Q4 2025, and $11.1 million in Q3 2025.